KR970702373A - 글리아 세포-유도 향신경 인자(GDNF)를 암호화하는 재조합 아데노바이러스(RECOMBINANT ADENOVIRUSES CODING FOR GLIAL-DERIVED NEUROTROPHlC FACTOR(GDNF)) - Google Patents

글리아 세포-유도 향신경 인자(GDNF)를 암호화하는 재조합 아데노바이러스(RECOMBINANT ADENOVIRUSES CODING FOR GLIAL-DERIVED NEUROTROPHlC FACTOR(GDNF))

Info

Publication number
KR970702373A
KR970702373A KR1019960705454A KR19960705454A KR970702373A KR 970702373 A KR970702373 A KR 970702373A KR 1019960705454 A KR1019960705454 A KR 1019960705454A KR 19960705454 A KR19960705454 A KR 19960705454A KR 970702373 A KR970702373 A KR 970702373A
Authority
KR
South Korea
Prior art keywords
adenovirus
gdnf
cell
dna sequence
promoter
Prior art date
Application number
KR1019960705454A
Other languages
English (en)
Other versions
KR100403707B1 (ko
Inventor
필리쁘 호렐로우
쟈끄 말레
프레데릭 르바
엠마누엘 빈느
미셀 페리코데
Original Assignee
자끄 사비나
롱프랑 로라 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자끄 사비나, 롱프랑 로라 소시에테 아노님 filed Critical 자끄 사비나
Publication of KR970702373A publication Critical patent/KR970702373A/ko
Application granted granted Critical
Publication of KR100403707B1 publication Critical patent/KR100403707B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

글리아-유도 향신경 인자(GDNF)를 암호화하는 이형 DNA 서열을 포함하는 재조합 아데노바이러스, 이의 제조 및 퇴행성 신경 질환을 치료하고/거나 예방하기 위한 이의 용도.

Description

글리아 세포-유도 향신경 인자(GDNF)를 암호화하는 재조합 아데노바이러스(RECOMBINANT ADENOVIRUSES CODING FOR GLIAL-DERIVED NEURO-TROPHlC FACTOR(GDNF))
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 벡터 pLTR IX-GDNF에 대한 설명.

Claims (26)

  1. GDNF 또는 그 유도체중 하나의 전부 또는 활성 부분을 암호화하는 적어도 하나의 DNA 서열을 포함하는 결손 재조합 아데노바이러스.
  2. 제1항에 있어서, DNA 서열이 GDNF를 암호화하는 서열과 함께 5′ 위치 및 판독 프레임에서 분비 서열을 포함함을 특징으로 하는 아데노바이러스.
  3. 제1항 또는 2항에 있어서, DNA 서열이 cDNA 서열임을 특징으로 하는 아데노바이러스.
  4. 제1항 또는 2항에 있어서, DNA 서열이 gDNA 서열임을 특징으로 하는 아데노바이러스.
  5. 제1항 내지 4항 중 어느 한 항에 있어서, DNA 서열이 사람 GDNF를 암호화함을 특징으로 하는 아데노바이러스.
  6. 제1항 내지 5항 중 어느 한 항에 있어서, DNA 서열이 신경 세포에서 이를 발현하게 하는 신호의 제어하에 배치됨을 특징으로 하는 아데노바이러스.
  7. 제6항에 있어서, 발현 신호가 바이러스 프로모터, 바람직하게는 EIA, MLP, CMV 및 RSV LTR 프로모터 중에서 선택됨을 특징으로 하는 아데노바이러스.
  8. 제1항에 있어서, RSV LTR 프로모터의 제어하에 사람 pre-GDNF를 암호화하는 cDNA 서열을 포함하는 결손 재조합 아데노바이러스.
  9. 제1항에 있어서, RSV LTR 프로모터의 제어하에 사람 pre-GDNF를 암호화하는 gDNA 서열을 포함하는 결손 재조합 아데노바이러스.
  10. 제1항에 있어서, 발현의 대부분이 신경 세포에서 일어날 수 있게 하는 프로모터의 제어하에, 글리아세포-유도 사람 향신경 인자(hGDNF) 또는 이의 유도체의 전부 또는 활성 부분을 암호화하는 DNA 서열을 포함하는 결손 재조합 아데노바이러스.
  11. 제10항에 있어서, 프로모터가 뉴런-특이성 에놀라제의 프로모터 및 GFAP 프로모터 중에서 선택됨을 특징으로 하는 결손 재조합 아데노바이러스.
  12. 제1항 내지 l1항 중 어느 한 항에 있어서, 표적 세포내에서 그의 복제를 위해 필요한 게놈의 일부가 결핍됨을 특징으로 하는 아데노바이러스.
  13. 제12항에 있어서, ITR 및 캡시드화를 허용하는 서열을 포함하고, E1 유전자 및 유전자 E2, E4 및 L1-L5 중 적어도 하나가 비-작용성임을 특징으로 하는 아데노바이러스.
  14. 제12항 또는 13항에 있어서, Ad2 또는 Ad5 사람 아데노바이러스 또는 CAV-2개 아데노바이러스임을 특징으로 하는 아데노바이러스.
  15. 퇴행성 신경 질환을 치료하고/거나 예방하기 위해 의도되는 제약학적 조성물을 제조하기 위한 제1항 내지 14항 중 어느 한 항에 따른 아데노바이러스의 용도.
  16. 제15항에 있어서, 파킨슨씨 병, 알쯔하이머 병, 헌팅톤 병 또는 ALS를 치료하고/거나 예방하기 위해 의도되는 제약학적 조성물을 제조하기 위한 용도.
  17. 제1항 내지 14항 중 어느 한 항에 따른 하나 또는 그 이상의 결손 재조합 아데노바이러스를 포함하는 제약학적 조성물.
  18. 제17항에 있어서, 주사가능한 형태임을 특징으로 하는 제약학적 조성물.
  19. 제17항 또는 18항에 있어서, 약 104내지 1014pfu/㎖, 바람직하게는 106내지 1010pfu/㎖의 결손 재조합 아데노바이러스를 포함함을 특징으로 하는 제약학적 조성물.
  20. 제1항 내지 14항 중 어느 한 항에 따른 하나 또는 그 이상의 결손 재조합 아데노바이러스로 감염된 포유 동물 세포.
  21. 제20항에 있어서, 사람 세포임을 특징으로 하는 세포.
  22. 제20항에 있어서, 섬유아세포, 근육아세포, 간세포, 내피 세포, 글리아 세포 또는 케라틴세포 유형의 사람 세포임을 특징으로 하는 세포.
  23. 제20항 내지 22항 중 어느 한 항에 따른 감염된 세포 및 세포의 매트릭스를 포함하는 이식물.
  24. 제23항에 있어서, 세포의 매트릭스가 바람직하게는 콜라겐, 젤라틴, 글루코스아미노글리칸, 피브로넥틴 및 렉틴 중에서 선택된 겔-형성 화합물을 포함함을 특징으로 하는 이식물.
  25. 제23항 또는 24항에 있어서, 세포외 매트릭스가 또한 감염된 세포를 부착시키기 위한 지지체를 포함함을 특징으로 하는 이식물.
  26. 제25항에 있어서, 지지체가 바람직하게는 폴리테트라플루오로에틸렌 섬유로 이루어짐을 특징으로 하는 이식물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960705454A 1994-03-25 1995-03-23 글리아세포-유도 향신경인자(gdnf)를 암호화하는 재조합 아데노 바이러스 KR100403707B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR94/03542 1994-03-25
FR9403542A FR2717824B1 (fr) 1994-03-25 1994-03-25 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (2)

Publication Number Publication Date
KR970702373A true KR970702373A (ko) 1997-05-13
KR100403707B1 KR100403707B1 (ko) 2004-02-11

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705454A KR100403707B1 (ko) 1994-03-25 1995-03-23 글리아세포-유도 향신경인자(gdnf)를 암호화하는 재조합 아데노 바이러스

Country Status (14)

Country Link
US (1) US6245330B1 (ko)
EP (1) EP0752004B1 (ko)
JP (1) JPH09510620A (ko)
KR (1) KR100403707B1 (ko)
AT (1) ATE335832T1 (ko)
AU (1) AU704910B2 (ko)
CA (1) CA2184841C (ko)
DE (1) DE69535155T2 (ko)
FI (1) FI963805A0 (ko)
FR (1) FR2717824B1 (ko)
IL (1) IL113109A0 (ko)
MX (1) MX9604024A (ko)
WO (1) WO1995026408A1 (ko)
ZA (1) ZA952433B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
WO1998046737A2 (en) * 1997-04-15 1998-10-22 University Of Medicine And Dentistry Of New Jersey cDNA FOR HUMAN GDNF AND PROMOTER THEREFOR WHICH ALLOWS REGULATED AND CONSTITUTIVE EXPRESSION
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
WO2003055983A2 (en) * 2001-12-21 2003-07-10 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
EP1694313A4 (en) * 2003-12-18 2010-11-17 Biomas Ltd TELLURIUM DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE PROCESSES
BRPI0710800A2 (pt) 2006-04-25 2012-01-17 Univ California administração de fatores de crescimento para o tratamento de distúrbios de snc
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
WO2008154644A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
MX2010012592A (es) 2008-05-20 2011-05-05 Eos Neuroscience Inc Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
US20140259192A1 (en) 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
WO2019174697A1 (en) 2018-03-15 2019-09-19 Coloplast A/S Apparatus and methods for navigating ostomy appliance user to changing room

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FR2717824A1 (fr) 1995-09-29
ZA952433B (en) 1996-01-15
EP0752004B1 (fr) 2006-08-09
DE69535155T2 (de) 2007-06-28
AU2141195A (en) 1995-10-17
DE69535155D1 (de) 2006-09-21
JPH09510620A (ja) 1997-10-28
WO1995026408A1 (fr) 1995-10-05
CA2184841A1 (fr) 1995-10-05
KR100403707B1 (ko) 2004-02-11
EP0752004A1 (fr) 1997-01-08
FI963805A (fi) 1996-09-24
FI963805A0 (fi) 1996-09-24
MX9604024A (es) 1997-09-30
US6245330B1 (en) 2001-06-12
ATE335832T1 (de) 2006-09-15
FR2717824B1 (fr) 1996-04-26
CA2184841C (fr) 2009-08-18
IL113109A0 (en) 1995-06-29
AU704910B2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
KR970702373A (ko) 글리아 세포-유도 향신경 인자(GDNF)를 암호화하는 재조합 아데노바이러스(RECOMBINANT ADENOVIRUSES CODING FOR GLIAL-DERIVED NEUROTROPHlC FACTOR(GDNF))
KR100375856B1 (ko) 치료물질의생체내생산을위한조성물
Hermens et al. Viral vectors, tools for gene transfer in the nervous system
Ware et al. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair
Akimoto et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.
Whitsett et al. Regulation of surfactant protein gene transcription
AU694097B2 (en) Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
AU712775B2 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
Zhang et al. Implantation of adult bone marrow-derived mesenchymal stem cells transfected with the neurotrophin-3 gene and pretreated with retinoic acid in completely transected spinal cord
Morelli et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity
CA2197235A1 (fr) Adenovirus comprenant un gene codant pour la glutathion peroxydase
US20030228295A1 (en) Use of human neural stem cells secreting GDNF for treatment of parkinson's and other neurodegenerative diseases
Holtmaat et al. Adenoviral Vector-Mediated Expression of B-50/GAP-43 Induces Alterations in the Membrane Organization of Olfactory Axon TerminalsIn Vivo
NO319571B1 (no) Anvendelse av et defektivt, rekombinant adenovirus.
Andreadis Gene transfer to epidermal stem cells: implications for tissue engineering
Dijkhuizen et al. Adenoviral vector-mediated gene delivery to injured rat peripheral nerve
US20040224409A1 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
Peltola et al. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse
CA2514781A1 (en) Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
Horellou et al. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease
KR970701785A (ko) 글루타메이트 디카르복실라제(gad) 활성을 암호화하는 재조합 바이러스(recombinant viruses coding for a glutamate decarboxylase(gad) activity)
KR970701784A (ko) 뇌-유도 향신경성 인자(BDNF)를 암호화하는 재조합 아데노비루스(Recombinant Adenoviruses Coding for Brain-Derived Neurotrophic Factor(BDNF))
US20050069523A1 (en) Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
Sortwell et al. Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival
Hodgson Basic and Clinical Aspects of Liver Growth: Prometheus Revisited: Humphry Davy Rolleston Lecture 1992

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee